INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit & a L...
January 09 2017 - 12:27PM
Business Wire
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Arrowhead Pharmaceuticals, Inc.
(“Arrowhead”) (NASDAQ:ARWR) between
May 11, 2015 and November 29, 2016. You are hereby
notified that a securities class action lawsuit has been
commenced in the USDC for the Central District of California. To
get more information go to:
http://www.zlk.com/pslra/arrowhead-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Arrowhead
made false and misleading statements and/or failed to disclose
that: (1) its drug candidate ARC-520 was fatal at certain doses;
(2) the U.S. Food & Drug Administration was unlikely to approve
ARC-520 as a hepatitis B treatment; (3) the Company overstated the
approval prospects and commercial viability of ARC-520; and (4) as
a result of the above, Arrowhead’s public statements were
materially false and misleading at all relevant times.
On November 8, 2016, after the close of the market, Arrowhead
Pharmaceuticals announced that the United States Food & Drug
Administration had decided to place a clinical hold on the
Company’s Heparc-2004 clinical study of ARC-520. Then on November
29, 2016, Arrowhead announced it would discontinue the development
of 3 hepatitis treatments and trim its workforce by 30 percent.
If you suffered a loss in Arrowhead you have until
January 17, 2017 to request that
the Court appoint you as lead plaintiff. Your ability to share in
any recovery doesn’t require that you serve as a lead
plaintiff.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation involving financial
fraud, and have recovered hundreds of millions of dollars for
aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad
Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free:
(877) 363-5972Fax: (212) 363-7171www.zlk.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109006096/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.(212) 363-7500,
toll-free: (877) 363-5972jlevi@zlk.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Sep 2023 to Sep 2024